Previous studies reported increased risk of acute myeloid leukaemia (AML) in individuals with inflammatory conditions. However, it is unclear whether this association is explained by preceding cytotoxic therapy or haematological diseases. We conducted a nationwide case-control study that included 3053 AML patients, diagnosed in Denmark between 2000 and 2013, and 30 530 sex-and age-matched population controls. We retrieved information on autoimmune disease, infections, and use of antibiotics and computed odds ratios for AML (conditional logistic regression). Results were stratified by AML type, sex, and age. Autoimmune diseases were associated with an overall increased risk of AML {odds ratio [OR] 1Á3 [95% confidence interval (CI) = 1Á1-1Á5]}. However, the risk was confined to patients with previous haematological disease or cytotoxic therapy exposure [secondary/therapy-related AML (sAML/tAML0) OR 2Á0 (95% CI = 1Á6-2Á6)] and not de novo AML [OR 1Á1 (95% CI = 0Á9-1Á3)]. Similarly, any prior infection requiring hospitalization was associated with a higher risk of AML [OR 1Á3 (95% CI = 1Á1-1Á4)]. Again, this association was evident for sAML/tAML [OR 1Á8 (95% CI = 1Á5-2Á2)], and not de novo AML [OR 1Á1 (95% CI = 1Á0-1Á2)]. In conclusion, autoimmune diseases and infections were associated with an increased AML risk only in subjects with prior haematological disease and/or cytotoxic treatment. These observations suggest, that inflammation plays -if any -a minor role for the development of de novo AML.
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Acute myeloid leukaemia (AML) is the most common acute leukaemia in adults, accounting for about 80% of cases. The age-adjusted incidence rate is 5Á4/100 000 person-years (Østgard et al, 2013) . One third of patients die within 6 months of diagnosis and less than 20% of patients are alive after 5 years (Danish National Acute Leukaemia Group, 2017) . Common known risk factors include a history of prior haematological diseases, most commonly myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs; secondary AML; sAML), and prior exposure to chemotherapy and/or radiotherapy (therapy-related AML; tAML) (Granfeldt Ostgard et al, 2015) . Although other risk factors, such as cigarette smoking (Kasim et al, 2005; Strom et al, 2012) , organic solvents (Kasim et al, 2005; Strom et al, 2012; Poynter et al, 2017) and obesity (Ross et al, 2004) , have been identified, the aetiology of AML remains unknown in up to 85% of new cases. These cases are referred to as de novo AML (Arber et al, 2016; Tomasetti et al, 2017) .
In line with the previously reported association between inflammatory conditions and lymphomas and certain solid cancers (Mantovani et al, 2008) , only few studies have been published on this topic and the majority of these studies have reported increased risk of myeloid malignancies in patients with chronic autoimmune diseases (Anderson et al, 2009; Kristinsson et al, 2011; Johnson et al, 2012; Ramadan et al, 2012) . However, due to the strong association between exposure to cytotoxic agents and subsequent AML (Larson, 2007) , and a lack of comprehensive clinical and prior exposure data in these studies, it remains unclear whether acute or chronic inflammation per se triggers AML transformation, or whether the increased risk reflects exposure to cytotoxic or immune modulating agents given to treat a variety of underlying autoimmune diseases.
Acute inflammation, including community-acquired infections, has been associated with an increased AML risk (Kristinsson et al, 2011; Titmarsh et al, 2014) . However, the interpretation of these results is also limited by lack of information on antecedent haematological diseases or cytotoxic therapy, both of which increases the risk of infections and AML. Thus, confounding may explain the observed association between an inflammatory state complicating a prior infectious episode and leukaemogenesis.
We aimed to investigate if acute and chronic inflammation, measured as infections requiring hospitalization, prior use of antibiotics as a proxy for community-acquired infections, as well as autoimmune diseases per se increase the risk of AML or whether prior cytotoxic therapy or haematological diseases may explain these associations. We combined several large Danish medical databases and performed a nationwide case-control study including all AML patients diagnosed between 2000 and 2013. We stratified results by type of AML (de novo, sAML/tAML.)
Methods
The source population was Danish residents older than 15 years (Danish population, 5Á7 million) (Statistics Denmark, 2017) observed from 2000 to 2014. All citizens are assigned a unique registration number (CPR number), which can be used to link data. All residents are provided with free tax-supported medical care.
AML cases
We identified all confirmed adult cases of AML diagnosed in Denmark during the study period. We excluded 125 patients with promyelocytic leukaemia from the study cohort due to the different pathogenesis. Cases and their date of diagnosis were identified through the Danish National Acute Leukaemia Registry (DNLR) (Østg ard et al, 2016a) .
To control for factors associated with antibiotic prescription, infection, autoimmune disease and the risk of AML, we retrieved data on AML type (de novo, sAML/tAML), with sAML defined as prior haematological disease and tAML defined as prior chemotherapy or radiotherapy given for a malignant or non-malignant disease not classified as sAML (Granfeldt Ostgard et al, 2015) .
Selection of population controls
We used the Civil Registration System (CRS) (Pedersen, 2011) and the Danish National Registry of Patients (DNRP) (Andersen et al, 1999) to select 10 controls for each AML case. The CRS is updated daily and records the vital status, date of death and residence of all Danish citizens. The DNRP includes information on all non-psychiatric hospital discharge diagnoses (in-hospital contacts since 1977, outpatient visits since 1995) registered according to the World Health Organization (WHO) International Classification of Diseases, revisions 8 and 10 (ICD8, ICD10). To be selected as controls, the general population members had to be alive without a history of AML .0 registered in the DNRP) at the diagnosis date of their matched AML patient.
We used risk set sampling (Rothman et al, 2008) and matched controls to cases by sex and date of birth. The index date for controls was defined as the date of AML diagnosis of their matched case.
Autoimmune disease and infections
To identify patients with autoimmune disease and/or infections prior to AML diagnosis or index date, we used ICD codes (primary and secondary diagnoses registered at any time in the DNRP (established in 1977) to identify the autoimmune diseases and infections listed in Table I (autoimmune diseases) and Table SI (infections).
We used non-haematological autoimmune disease diagnoses categorized into five subgroups based on disease location or tissue of origin: endocrine disease, gastrointestinal (GI)/hepatic/biliary disease, skin disease, rheumatological disease and vasculitis syndromes.
Inflammation caused by infectious agents was measured as any in-hospital contact involving infections prior to AML diagnosis or the index date. Infections were categorized into 19 categories based on infectious agents (e.g. bacterial, viral) and target of the infection.
Use of antibiotics
To capture infections without hospital contact, we obtained antibiotic prescription data through the Danish National Health Service Prescription Database (Johannesdottir et al, 2012) . The database, which is maintained by the Danish Medicines Agency, includes information on all prescribed drugs dispensed from Danish pharmacies. Information includes the CPR number, date of prescription and type of drug prescribed according to the WHO Anatomical Therapeutic Chemical (ATC) classification system. We used the ATC codes J01C xxx (except J01CA08 and J01CA11) to identify prescriptions for any antibiotic redeemed before the diagnosis date of AML cases or the index date for controls. In Denmark, antibiotics are available only by prescription. Prescription data were available for the period 1995-2013, allowing a minimum 5-year opportunity for exposure.
Statistical analysis
We computed frequencies and proportions of cases and controls by disease exposure (infections and autoimmune disease) as well as by categories of drug exposure (antibiotics) and the covariates.
We used conditional logistic regression analysis to estimate the odds ratio (OR) associating AML with autoimmune disease, infections, and antibiotic use. Given the risk set sampling of controls, ORs in conditional logistic regression are valid estimates of the corresponding incidence rate ratios.
To minimize the risk of reverse causality and detection bias, we ignored prescriptions and infections and autoimmune diagnoses registered in immediate relation to AML diagnosis. We used 3-year in the primary analysis and 1 year was included to test the robustness of the results.
We only reported results for specific autoimmune diagnoses with prevalence >0Á5% and specific infections with at least five infections among cases to ensure adequate power to detect a difference between cases and controls. For risk of any autoimmune disease or infections, we included all disease groups listed in Tables I and SII. All results were given overall and stratified by type of AML. Due to small numbers of tAML patients, tAML and sAML patients were combined, justified by comparable overall estimates. Results were stratified by sex and age (<60, ≥60 years), Results were provided with 95% confidence intervals (CIs).
Analyses were performed using SAS, version 9.4 (SAS Institute Inc., Cary, NC, USA). The study was approved by the Danish Data Protection Agency (jr.nr. 2013-41-1570) .
Results
The case-control study included 3053 AML cases and 30 530 population controls matched by sex and age. Descriptive 2015, 2016b, 2017) .
Autoimmune diseases
The associations between autoimmune diseases overall, for, and sAML/tAML patients are shown in Fig 1 (1-year exclusion, Table SII) . Overall, any prior diagnosis of an autoimmune disease was associated with an increased risk of AML [OR (conditional on sex and age) 1Á3 (95% CI = 1Á1-1Á6)]. The relative risk of AML was similar between patients with GI and hepato-biliary diseases [OR 1Á4 (95% CI = 1Á0-2Á0)], rheumatological disease [OR 1Á4 (95% CI = 1Á2-1Á8)], and vascular syndromes [OR 1Á4 (95% CI = 1Á0-2Á0)]. Also, patients with cutaneous autoimmune diseases had increased risk of AML, although results were not significant. When stratified by type of AML, the overall associations were limited only to patients with a previous history of haematological disease or exposure to cytotoxic therapy [risk of sAML/tAML: any autoimmune disease OR 2Á0 (95% CI = 1Á6-2Á6), skin disease OR 3Á3 (95% CI = 1Á7-6Á5), rheumatological disease OR 2Á5 (95% CI = 1Á8-3Á5), and vasculitis OR 2Á2 (95% CI = 1Á2-3Á9)]. In patients with de novo AML, a history of any pre-existing autoimmune disease was not associated with risk of AML [OR 1Á1 (95% CI = 0Á9-1Á3)], despite a positive association between GI and hepato-biliary autoimmune diseases and de novo AML [1Á5 (95% CI = 1Á0-2Á2)].
As shown in Fig 1, the overall estimated associations between individual autoimmune diseases and AML were similar across the sexes. However, for GI and hepato-biliary diseases the associations were stronger for women [women OR 1Á8 (95% CI = 1Á1-2Á9) vs. men OR 1Á1 (95% CI = 0Á7-1Á9)] and younger patients [<60 years: OR 2Á0 (95% CI = 1Á1-3Á5) vs. ≥60 years OR 1Á3 (95% CI = 0Á8-1Á9)].
Changing the exposure definition to autoimmune diseases registered from more than 3 years to up to 1 year prior to AML diagnosis or index date did not substantially change the estimates.
Use of antibiotics and community-acquired infection
Overall, 2451 patients (80Á3%; de novo AML 78Á3%, sAML/ tAML 85Á7%) had redeemed a prescription for antibiotics during the years 1995-2013 and more than 3 years before AML diagnosis. Among the 30 530 controls, 78Á0% had redeemed at least one prescription during the years 1995-2013 and more than 3 years before their index date.
The associations between use of antibiotics and risk of AML are shown in Table III (1 year exclusion only, Table SIII) .
Any use of antibiotic therapy more than 3 years before the diagnosis date of AML or the control's index date was associated with a higher risk of AML [OR 1Á2 (95% CI 1Á1-1Á3)]. However, when stratified by AML type, the association was limited to patients with sAML/tAML [OR 1Á8 (95% CI = 1Á5-2Á2)], whereas the risk of de novo AML [OR 1Á0 (95% CI = 0Á9-1Á1)] was not increased. Associations were comparable across sex and age groups. Several individual infectious groups were associated with an increased risk of AML [e.g. pneumonia, OR 1Á4 (95% CI = 1Á2-1Á7)], mostly due to a higher association with sAML/tAML (Fig 2) . In contrast, only GI infections were associated with an increased risk of de novo AML [OR 1Á5 (95% CI = 1Á1-2Á0)] with bacteraemia and abscess being borderline significant. To investigate whether an increased risk of AML in patients previously hospitalized with GI infections were associated with GI autoimmune disease, we repeated the analyses excluding patients with a GI autoimmune disorder, but this did not change this estimates.
Hospitalization-requiring infections
In general, using only 1-year exclusion of infections defining exposure resulted in higher estimates (Table SIV) .
Discussion
This large national population-based case-control study confirms previous reports of increased risk of AML in patients
Characteristics
Odds ratio (95% CI) † Cases, n (%) with autoimmune diseases and community-acquired or hospital-requiring infections, but this association appears to be limited to patients with sAML and/or tAML. Thus, our findings suggest that inflammation without exposure to cytotoxic or immune-modulating agents plays a minor role in leukaemogenesis. To our knowledge, this is the first study to investigate the association between autoimmune diseases and infections and risk of AML for de novo and sAML/tAML, separately. The mechanisms responsible for this increased association remain elusive. However, chronic inflammatory conditions are associated with accumulation of reactive oxygen species and oxidative damage to the DNA, which may lead to increased genomic instability and increased risk of mutations (Hasselbalch, 2013) . Recently, a negative impact of the proinflammatory cytokine c-interferon (IFNc) was reported on human haematopoetic stem and progenitor cell maintenance in bone marrow failure syndromes (Alvarado et al, 2017) . Also, clonal haematopoiesis was recently described as an agerelated event associated with expansion of phenotypically normal haematopoietic progenitors following the spontaneous acquisition of mutations in genes important in myeloid development. Clonal haematopoiesis is associated with >10-fold increase in the development of advanced myeloid malignancies, particularly following exposure to cytotoxic agents and radiotherapy (Jaiswal et al, 2014) . Thus, chronic inflammatory conditions may contribute secondary and subsequent mutagenic events that culminate in clonal haematopoiesis and eventually predispose to transformation into AML. This may explain the association between chronic inflammation and sAML/t-AML, but not de novo AML.
As for chronic inflammatory stimulation, we did not find an association between short-term inflammatory exposure measured as infections and de novo AML. Though, this is in contrast to, e.g. the known association between Epstein-Barr infections and Burkitt lymphomas, and a previous suggested hypothesis that early childhood infections predispose to childhood acute lymphoblastic leukaemia through a deregulated immune response to the infectious agents (Roman et al, 2007) , an association between B cell activation and development of myeloid malignancies is less likely and may explain our results. In addition, it has been previously described that IFNc, a key pro-inflammatory cytokine, is implicated in the destruction of Hematopoietic Stem/Progenitor Cells in bone marrow failure syndromes (Alvarado et al, 2017 95% CI, 95% confidence interval; AML, acute myeloid leukaemia; sAML, secondary acute myeloid leukaemia; tAML, therapy-related acute myeloid leukaemia. *Prescriptions was recorded from 1995 through the calendar 1 and 3 years before the date of AML diagnosis. †Conditional on date of birth and sex. †Conditional on date of birth and sex. Parasitic infections, human immunodeficiency virus, atypical mycobacteria, tuberculosis, meningitis, viral hepatitis, heart infections, and septic arthritis were included in the overall estimates, however, they were not common enough to include in the subgroup analysis. 95% CI, 95% confidence interval; AML, acute myeloid leukaemia; sAML, secondary acute myeloid leukaemia; tAML, therapy-related acute myeloid leukaemia. with thrombopoietin (TPO), resulting in impaired receptor dimerization and perturbation of TPO-induced signalling, which results in decreased survival of human haematopoietic stem/progenitor cells (Alvarado et al, 2017) . The lack of treatment details in prior studies precluded the authors drawing conclusions about the leukaemogenic role of autoimmune diseases (Ramadan et al, 2012) . Most prior studies used only self-reported disease information, limited inclusion of subjects from different age groups and lack of therapy for autoimmune disorders (Anderson et al, 2009; Ramadan et al, 2012) . Conversely, we used data on both antibiotic prescription redemption and data on infections requiring hospitalizations. Using this approach, we found that the increased risk of AML was limited to subjects with a history of sAML/tAML. Although two previous studies (Kristinsson et al, 2011; Titmarsh et al, 2014) reported an increased risk of MDS and AML [OR 1Á3 (95% CI = 1Á2-1Á4)] in subjects with prior infections, these studies were also limited by lack data on prior treatments, and data on antecedent haematological disorders and/or tAML. To minimize reverse causality, we limited exposures closely related to time of the AML diagnosis (<3 years). In general, higher estimates of AML diagnosis are observed following shorter exclusion periods (e.g. 1 year vs. 3 years), which probably reflect the higher association between prior infections and AML in patients with clinically silent or undiagnosed antecedent haematological disorders, such as MDS, MPNs or MDS/ MPN overlap syndromes.
Our findings confirm the increased risk of AML across strata for GI (GI) disease, such as inflammatory bowel diseases, which may be a result of use of azathioprine, previously reported to be leukaemogenic (Ramadan et al, 2012) , or other immune-modulating agents for control of these inflammatory disorders (Anderson et al, 2009; Johnson et al, 2012) . Unfortunately, prior treatment with azathioprine or other immune-modulating agents is not captured by the DNLR. Additionally, immune-modulating agents are rarely used to treat autoimmune endocrine diseases, which may explain the lack of association between endocrine diseases and AML overall or within strata. Interestingly, we also found an increased risk of AML across strata in patients with prior GI infections and bacteraemia that was unrelated to GI autoimmune diseases and possible azathioprine use. Although this may be a coincidental finding, we cannot rule out the possibility that infections or autoimmune diseases in the GI tracts cause immune-related/inflammation-driven leukaemogenesis from unique and unknown mechanisms. Although speculative, the GI tract is crucial to the homeostasis of both the innate and adaptive immune system and disturbance of the immune-microbiome equilibrium could have profound effects (Cisalpino et al, 2017) .
Though AML is a heterogenetic disease, our main findings were consistent across age and gender, strengthening our conclusions. Also, the magnitude of our overall and non-stratified results is consistent with previous reports (Kristinsson et al, 2011) . Other strengths include the national population-based design including all adult AML cases over a 14-year period. The use of multiple gender-and age-matched populationbased controls reduced selection bias and increases the generalizability of the study results. Data on exposures was retrieved from high-quality registries, which prospectively collects data of purposes independent of our study aims, thereby reducing the risk of recall bias, which may otherwise hamper the results of case-control studies. The accuracy of the AML diagnosis and the coverage in the DNLR is high (>99%) and the validity of information used to group de novo AML, sAML and tAML diagnosis were accurate (>95%).
Our study has limitations. We lacked information on severity of autoimmune diseases and given that information was collected using hospital data, the incidence could have been underestimated. However, any under-reporting is suspected to be similar in cases and controls and cannot explain the results for tAML/sAML patients. We do not know whether patients who redeemed antibiotic prescriptions were compliant with their treatment. However, given that its use was a proxy for community-acquired infections, adherence is of less importance. Also, adherence is expected to be similar between cases and controls and any non-differential misclassification is unlikely to explain our results of the stratified analysis also considering the consistency of results for use of antibiotics and infections.
We were not able to adjust for potential confounders (e.g. socioeconomics or lifestyle factors) except age and gender, which may have influenced the results. The multiple comparison approach may have resulted in significant associations simply happening by chance, and any sub-analyses must be interpreted with caution. However, these analyses were primarily used to investigate the predefined hypothesis of no association between autoimmune diseases, infections and AML in persons not exposed to cytotoxic therapy or previous haematological disorders (Rothman, 2014) . The consistency of the analyses stratified by type of AML across exposures (antibiotics, infections, autoimmune diseases) and across sex and age groups reduces the likelihood of our conclusions relying on coincidences.
Conclusion
This large population-based study using high-quality data shows that inflammatory conditions, identified by infections, autoimmune diseases and prior use of antibiotics, are not associated with de novo AML. An interesting exception was the association between GI autoimmune diseases and GI infections and an increased risk of de novo AML. Alhough we cannot rule out the possibility that infections or autoimmune diseases in relation to the GI tracts cause immunerelated/inflammation-driven leukaemogenesis, these findings require independent validation and may be explained by therapeutic immune-modulating agents increasing both risk of infections and AML.
In summary, our results indicate that in patients without prior haematological disease or exposure to cytotoxic therapy, inflammation plays -if any -only a minor role in AML leukaemogenesis.
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